Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK; Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA. Kok PS, et al. BMJ Open. 2022 Jan 25;12(1):e057663. doi: 10.1136/bmjopen-2021-057663. BMJ Open. 2022. PMID: 35078853 Free PMC article.
A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice.
Mercieca-Bebber R, Friedlander M, Calvert M, Stockler M, Kyte D, Kok PS, King MT. Mercieca-Bebber R, et al. Among authors: kok ps. J Patient Rep Outcomes. 2017;1(1):5. doi: 10.1186/s41687-017-0008-3. Epub 2017 Oct 4. J Patient Rep Outcomes. 2017. PMID: 29757300 Free PMC article.
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, Pavlakis N, Briscoe K, O'Byrne KJ, Karapetis CS, Lam WS, Langford A, Yip S, Stockler MR. Nowak AK, et al. Among authors: kok ps. Lancet Oncol. 2020 Sep;21(9):1213-1223. doi: 10.1016/S1470-2045(20)30462-9. Lancet Oncol. 2020. PMID: 32888453 Clinical Trial.
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, Spurdle A, Barnes E, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Andrews J, Stockler MR, Mileshkin L; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Antill Y, et al. Among authors: kok ps. J Immunother Cancer. 2021 Jun;9(6):e002255. doi: 10.1136/jitc-2020-002255. J Immunother Cancer. 2021. PMID: 34103352 Free PMC article. Clinical Trial.
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).
Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Smith D, et al. Among authors: kok ps. Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254. Cancers (Basel). 2022. PMID: 36612250 Free PMC article.
23 results